Cognitive Studies for Cancer Survivors in India: Is This the Right Time or Should we Cross the Bridge only When we will Come to it?

Introduction and Rationale

Cancer is gradually emerging as leading cause of deaths in India with more than 2.5 million patients suffering from the disease.[1] This increase in incidence can either be attributed to increased lifespan and better diagnostic techniques or it may reflect a realistic pattern due to exposure to risk factors for cancer.

India is still grappling with overwhelmingly poor outcomes in cancer patients due to a variety of reasons including late stages at presentation, delay in diagnosis due to poor referral system, capricious public health-care system and infrastructure, high abandonment rates, and lack of availability of newer drugs, whereas developed world is now focusing on perspectives such as de-escalation of therapies, preservation of fertility, cardiotoxicity, and cognitive issues that help cancer survivors getting better quality of life (qol) and living a more productive life. Through this commentary, we have focused on the aspect of cognition related to chemotherapy or cancer per se and its relevance to India. Besides, we have also proposed the schema of studies that need to be conducted and challenges ahead.

Cancer-induced cognitive dysfunction encompasses range of difficulties that tend to include relatively subtle changes in memory, concentration, and executive function that can show up in the weeks during and months after completion of cancer treatment and persist thereafter in up to 75% of cancer patients.[2]

The etiology of cognitive deficits in cancer patients could be multifactorial (psychological stress, occurrence of cancer itself, brain irradiation, intrathecal chemotherapy, direct treatment for brain cancer or metastasis, and systemic chemotherapy). Its importance lies in the significant distress in professional reintegration, interpersonal relationships, and leisure activities. This might also affect future qol and might bring a feeling of worthlessness.

Publikationsverlauf

Artikel online veröffentlicht:
17. Juni 2021

• References

• 1 Sequeira AK, Sequeira AZ, Krishnamurthy K. Study of cognitive functions in breast cancer patients: A case control study. Muller J Med Sci Res 2014; 5: 129-33
• 2 Jean-Pierre P. Management of cancer-related cognitive dysfunction-conceptualization challenges and implications for clinical research and practice. US Oncol 2012; 6: 9-12
• 3 Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005; 104: 2222-33
• 4 Cruzado JA, López-Santiago S, Martínez-Marín V, José-Moreno G, Custodio AB, Feliu J. et al. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support Care Cancer 2013; 22: 1815-23
• 5 Simó M, Root JC, Vaquero L, Ripollés P, Jové J, Ahles T. et al. Cognitive and brain structural changes in a lung cancer population. J Thorac Oncol 2015; 10: 38-45
• 6 Kaur S, Sharma R, Rastogi S. Demystifying the association of chemotherapy and cognition: How close are we? J Clin Oncol 2016 pii: JCO687400
• 7 Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA. et al. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology 2014; 23: 626-33
• 8 Jacola LM, Krull KR, Pui CH, Pei D, Cheng C, Reddick WE. et al. Longitudinal assessment of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy protocol. J Clin Oncol 2016; 34: 1239-47
• 9 Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T. et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007; 109: 146-56
• 10 Jenkins V, Thwaites R, Cercignani M, Sacre S, Harrison N, Whiteley-Jones H. et al. A feasibility study exploring the role of pre-operative assessment when examining the mechanism of ‘chemo-brain’ in breast cancer patients. Springerplus 2016; 5: 390
• 11 Menning S, de Ruiter MB, Veltman DJ, Boogerd W, Oldenburg HS, Reneman L. et al. Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. PLoS One 2017; 12: e0171724
• 12 Bruno J, Hosseini SM, Kesler S. Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis 2012; 48: 329-38
• 13 Moore HC, Parsons MW, Yue GH, Rybicki LA, Siemionow W. Electroencephalogram power changes as a correlate of chemotherapy-associated fatigue and cognitive dysfunction. Support Care Cancer 2014; 22: 2127-31
• 14 Junghöfer M, Elbert T, Leiderer P, Berg P, Rockstroh B. et al. Mapping EEG-potentials on the surface of the brain: A strategy for uncovering cortical sources. Brain Topogr 1997; 9: 203-17
• 15 Robinson AK, Venkatesh P, Boring MJ, Tarr MJ, Grover P, Behrmann M. et al. Very high density EEG elucidates spatiotemporal aspects of early visual processing. Sci Rep 2017; 7: 16248
• 16 Brodbeck V, Spinelli L, Lascano AM, Wissmeier M, Vargas MI, Vulliemoz S. et al. Electroencephalographic source imaging: A prospective study of 152 operated epileptic patients. Brain 2011; 134: 2887-97
• 17 Lindenbeg A. From maps to mechanisms through neuroimaging of schizophrenia. Nature 2010; 468: 194
• 18 Mathan S, Smart A, Ververs T, Feuerstein M. Towards an index of cognitive efficacy EEG-based estimation of cognitive load among individuals experiencing cancer-related cognitive decline. Conf Proc IEEE Eng Med Biol Soc 2010; 2010: 6595-8
• 19 Alvarez J, Meyer FL, Granoff DL, Lundy A. The effect of EEG biofeedback on reducing postcancer cognitive impairment. Integr Cancer Ther 2013; 12: 475-87